Chapter 12 of 25
- Confirm CIN or AIS and exclude invasion
- Select surveillance, ablation or excision
- Review specimen and margins where available
- Continue risk-based surveillance
What you will learn
Compare observation, ablation and excision; understand CIN and AIS pathways; plan follow-up and fertility discussions.
When observation is appropriate
CIN1 often regresses, so surveillance is commonly preferred over immediate treatment. Selected CIN2 may be monitored when a specialist judges observation safe, especially when future pregnancy is important and the entire relevant area can be assessed. This requires reliable attendance, specified repeat testing and a clear trigger for treatment. CIN3 generally requires treatment, with pregnancy-specific exceptions managed by specialists.
Observation is active care, not ignoring the result. If attendance is difficult, tell the team so they can choose a workable strategy. Age, immune suppression, persistence, canal involvement and uncertainty about invasion can change the balance. A generic screening interval should not replace a post-biopsy plan.
Ablation versus excision
Ablation destroys abnormal tissue using heat or freezing. It may be appropriate in a screened, eligible lesion when invasion and glandular disease are not suspected and the lesion can be adequately visualized and treated. Because no specimen remains for full examination, selection is crucial. Large lesions, extension into an unseen canal or concern for cancer usually need a different approach.
LEEP, also called LLETZ, uses an electrical loop to remove tissue. Cold-knife conization removes a cone-shaped specimen surgically. Excision permits assessment of the lesion and margins, and can reveal previously unrecognized invasion. The appropriate technique and depth depend on the diagnosis, anatomy and need for an intact specimen, rather than one procedure being best for everyone.
Glandular precancer needs particular care
AIS can extend within the canal and have separate areas of disease. Diagnostic excision is important to exclude invasive adenocarcinoma and assess margins. Hysterectomy is often discussed after childbearing when AIS is confirmed, while fertility-sparing management may be considered only with adequate excision, acceptable margins and close specialist surveillance. Negative margins reduce concern but do not remove the need for follow-up.
A positive margin does not automatically dictate one operation. The tissue diagnosis, margin location, residual risk and reproductive goals guide whether repeat excision, surveillance or further surgery is appropriate. Invasive disease found in an excision changes the pathway and may require staging.
Recovery and future pregnancy
Expect individualized instructions about bleeding, discharge, intercourse, exercise and infection signs. Seek help for heavy bleeding, fever or increasing pain. Excisional treatment, especially deeper or repeated procedures, can increase the risk of later preterm birth. This does not mean pregnancy is impossible; tell future obstetric clinicians about the procedure and bring the pathology report.
After treatment, HPV-based surveillance is often used to assess ongoing risk. Under US risk-based guidance, high-grade disease requires long-term surveillance extending at least 25 years, even beyond usual screening age. Other systems may organize follow-up differently. Vaccination may still be discussed, but does not replace surveillance or cure residual HPV.
Misconception and common question
“Removing the abnormal area means screening can stop forever” is false. Is hysterectomy the standard treatment for every CIN lesion? No; many lesions are managed with surveillance or local treatment, and hysterectomy has its own risks.
Take-home messages
Match treatment to the exact lesion and visibility. Discuss future pregnancy before excision. Leave with written pathology, recovery advice and a long-term follow-up plan.
References and review status
- ASCCP — Risk-based management consensus guidelines and resources
- WHO — Screening and treatment recommendations, 2021
- Cibula et al. ESGO/ESTRO/ESP cervical cancer guidelines, 2023 update
Evidence/editorial check: 28 October 2026. AI-assisted preparation is separate from physician sign-off. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy